VB15010 for advanced solid tumors with HRR gene mutation
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an oral medication (VB15010) in people with advanced solid tumors that have a specific DNA repair gene mutation (called HRR mutation). The goal is to see if the drug can stop or slow down cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have an advanced solid tumor that has been confirmed by a biopsy or lab test.
- Your cancer is currently growing or spreading despite previous treatments.
- You have a genetic mutation in the HRR pathway (like BRCA, ATM, or other DNA repair genes).
- You have not had major surgery in the last 4 weeks, and any brain or spinal cord metastases are stable and not requiring high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.